AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData
Most of Lynparza’s sales come from ovarian and HER2-negative breast cancer treatment
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lynparza
NATCO announces ANDA filing for generic olaparib tablets in US
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer
DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast…
New data from Olympia phase-III trial suggest that Olaparib demonstrated a statistically significant and clinically meaningful…
EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative…
It is the first and only approved medicine targetting BRCA mutations in early breast cancer
Merck to stop Keylynk-010 trial evaluating Keytruda in combination with Lynparza
In an interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in the overall survival, one of the…
LYNPARZA (olaparib) get three new approvals in Japan
Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials
AstraZeneca gets DCGI nod to import and market Olaparib film coated tablets
It is additionally indicated as a monotherapy to treat adults with metastatic castration-resistant prostate cancer and homologous…
AstraZeneca-Merck’s Lynparza wins approval in China for ovarian cancer treatment,
The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or…
AstraZeneca’s Tagrisso helps lung cancer patients live longer: study
The British drugmaker announced overall positive survival results from the study in patients with epidermal growth factor…